1. Intensive chemotherapy for solid tumours—Current clinical applications

   • Stanley B. Kaye

   Review Pages: 127 - 133

2. A new nitrosourea derivative TA-077, 1-(2-Chloroethyl)-3-isobutyl-3-(β-maltosyl)-1-nitrosourea

   • S. Fujimoto
   • M. Ogawa

   Original Articles Pages: 134 - 139

3. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II

   • A. H. Calvert
   • S. J. Harland
   • K. R. Harrap

   Original Articles Pages: 140 - 147

4. Role of the host in the variable chemotherapeutic response of advanced Ridgway osteogenic sarcoma

   • J. Arly Nelson
   • James A. Hokanson
   • Vernon K. Jenkins

   Original Articles Pages: 148 - 155

5. High-dose methotrexate: A clinical and pharmacokinetic evaluation

   • R. Favre
   • S. Monjanel
   • Y. Carcassonne

   Original Articles Pages: 156 - 160

6. Effects of polysorbate 80 on the absorption and distribution of oral methotrexate (MTX) in mice

   • M. Noor Azmin
   • James F. B. Stuart
   • Alexander T. Florence

   Original Articles Pages: 161 - 164

7. Effect of combination chemotherapy, duration of methotrexate administration, and Patient's age on methotrexate pharmacokinetics

   • François Lokiec
   • Odette Poirier
   • Yves Najean

   Original Articles Pages: 165 - 168

8. Clinical pharmacology of bruceantin by radioimmunoassay

   • K. L. L. Fong
   • D. H. W. Ho
   • G. P. Bodey

   Original Articles Pages: 169 - 172

9. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients

   • B. J. McDermott
   • H. W. van den Berg
   • R. F. Murphy

   Original Articles Pages: 173 - 178

10. Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy

    • V. M. Macaulay
    • R. H. J. Begent
    • E. S. Newlands

    Short Communication Pages: 179 - 181

11. Erratum

    Erratum Pages: 182 - 182